Phillips-Medisize Corporation, a global leader in outsource design, development and manufacturing services for the medical industry announced Wednesday that it has entered into a binding agreement to be acquired by Molex LLC (Molex), a global manufacturer of complete interconnectsolutions.

Headquartered in Hudson, Phillips-Medisize is a portfolio company of San Francisco, Calif.-based Golden Gate Capital, a private equity investment firm with approximately $15 billion of capital under management.

Phillips-Medisize employs more than 4,300 people in 17 production locations throughout the United States — including Menomonie, Europe, Mexico and China. Molex designs and manufactures electronic, electrical and fiber optic systems and solutions. As one of the world’s largest interconnect companies, Molex employs more than 40,000 people in more than 40 countries.

“Molex and Phillips-Medisize share a similar culture and approach to managing the business that creates strong partnerships built on quality and innovation,” said Matt Jennings, chairman, president and CEO of Phillips-Medisize Corporation. “Molex’s global scale in electronics, coupled with Phillips-Medisize’s strength in designing and manufacturing innovative products for medical device customers, will help us become a global leader in connected health solutions.”

According to Tim Ruff,senior vice president of business development and corporate strategy for Molex LLC, “Phillips-Medisize has a talented, experienced and innovative team that has strong customer relationshipsbecause of its outstanding ability to serve the unique needs of the medical solutions market. Combined with Molex’s expertise in electronics and broad global manufacturing presence, we are confident that together we can significantly expand our medical solutions capabilities globally.”

Rajeev Amara, a managing director of Golden Gate Capital stated, “In just three years of our ownership, Phillips-Medisize has executed on a transformative vision to become a global leader in the manufacturing of biologics drug delivery devices. We would like to thank all the employees for their hard work and wish them well in the future.”

Terms of the transaction were not disclosed. The transaction is subject to customary closing conditions and is expected to close in the fall.

Be the first to know

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.